Vistagen Therapeutics Inc (VTGN)
4.47
-0.19
(-4.08%)
USD |
NASDAQ |
May 08, 16:00
4.47
0.00 (0.00%)
After-Hours: 20:00
Vistagen Therapeutics Enterprise Value: -0.6218M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | -0.6218M |
| May 06, 2024 | -1.703M |
| May 03, 2024 | -4.946M |
| May 02, 2024 | -7.378M |
| May 01, 2024 | 1.540M |
| April 30, 2024 | 3.972M |
| April 29, 2024 | 2.351M |
| April 26, 2024 | 1.810M |
| April 25, 2024 | 0.4592M |
| April 24, 2024 | 0.9997M |
| April 23, 2024 | 3.972M |
| April 22, 2024 | 2.621M |
| April 19, 2024 | 2.081M |
| April 18, 2024 | 0.4592M |
| April 17, 2024 | -0.3515M |
| April 16, 2024 | -0.892M |
| April 15, 2024 | 1.810M |
| April 12, 2024 | 5.594M |
| April 11, 2024 | 16.81M |
| April 10, 2024 | 11.27M |
| April 09, 2024 | 18.57M |
| April 08, 2024 | 13.16M |
| April 05, 2024 | 9.648M |
| April 04, 2024 | 16.40M |
| April 03, 2024 | 18.84M |
| Date | Value |
|---|---|
| April 02, 2024 | 19.38M |
| April 01, 2024 | 19.38M |
| March 28, 2024 | 16.13M |
| March 27, 2024 | -3.054M |
| March 26, 2024 | -9.000M |
| March 25, 2024 | -10.89M |
| March 22, 2024 | -13.86M |
| March 21, 2024 | -12.65M |
| March 20, 2024 | -13.86M |
| March 19, 2024 | -14.40M |
| March 18, 2024 | -16.84M |
| March 15, 2024 | -17.11M |
| March 14, 2024 | -20.62M |
| March 13, 2024 | -13.05M |
| March 12, 2024 | -16.03M |
| March 11, 2024 | -13.86M |
| March 08, 2024 | -12.78M |
| March 07, 2024 | -12.11M |
| March 06, 2024 | -6.838M |
| March 05, 2024 | -5.216M |
| March 04, 2024 | 4.513M |
| March 01, 2024 | 10.46M |
| February 29, 2024 | 11.54M |
| February 28, 2024 | 14.24M |
| February 27, 2024 | 16.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-21.37M
Minimum
Jul 29 2022
562.89M
Maximum
Jul 01 2021
105.29M
Average
36.84M
Median
Oct 06 2020
Enterprise Value Benchmarks
| Ardelyx Inc | 2.069B |
| Axsome Therapeutics Inc | 3.503B |
| Vir Biotechnology Inc | 202.66M |
| Immuneering Corp | -39.41M |
| NovaBay Pharmaceuticals Inc | 2.560M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.350M |
| Revenue (Quarterly) | 0.4114M |
| Total Expenses (Quarterly) | 8.296M |
| EPS Diluted (Quarterly) | -0.22 |
| Profit Margin (Quarterly) | -1.54K% |
| Earnings Yield | -78.50% |
| Normalized Earnings Yield | -78.50 |